coronavirus
cov
emerg
anim
reservoir
caus
sever
lethal
diseas
human
current
fdaapprov
antivir
treat
infect
one
class
antivir
compound
nucleosid
analogu
mimic
natur
occur
nucleosid
inhibit
viral
replic
compound
success
therapeut
sever
viral
infect
mutagen
nucleosid
analogu
ribavirin
ineffect
inhibit
cov
attribut
proofread
activ
viral
exoribonucleas
exon
hydroxycytidin
nhc
emori
institut
drug
develop
recent
report
inhibit
multipl
virus
demonstr
nhc
inhibit
murin
hepat
viru
mhv
effect
concentr
ec
middl
east
respiratori
syndrom
cov
merscov
ec
minim
cytotox
nhc
inhibit
mhv
lack
exon
proofread
activ
similarli
wildtyp
wt
mhv
suggest
abil
evad
overcom
exon
activ
nhc
inhibit
mhv
ad
earli
infect
decreas
viral
specif
infect
increas
number
proport
g
c
u
transit
mutat
present
singl
infect
lowlevel
nhc
resist
difficult
achiev
associ
multipl
transit
mutat
across
genom
mhv
merscov
result
point
virusmutagen
mechan
nhc
inhibit
cov
indic
high
genet
barrier
nhc
resist
togeth
data
support
develop
nhc
treatment
cov
suggest
novel
mechan
nhc
interact
cov
replic
complex
may
shed
light
critic
aspect
replic
import
emerg
coronavirus
cov
human
popul
anim
reservoir
demonstr
epidem
capabl
pandem
potenti
abil
caus
sever
diseas
howev
antivir
approv
treat
infect
demonstr
potent
antivir
activ
broadspectrum
ribonucleosid
analogu
hydroxycytidin
nhc
two
diverg
cov
viral
proofread
activ
markedli
impact
sensit
nhc
inhibit
suggest
novel
interact
nucleosid
analogu
inhibitor
cov
replicas
passag
presenc
nhc
gener
lowlevel
resist
like
due
accumul
multipl
potenti
deleteri
transit
mutat
togeth
data
support
mutagen
mechan
inhibit
nhc
support
develop
nhc
treatment
cov
infect
keyword
coronaviru
nucleosid
analogu
rdrp
rnadepend
rna
polymeras
sarscov
merscov
pandem
antivir
resist
emerg
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
underscor
abil
coronavirus
cov
caus
lethal
diseas
human
merscov
continu
infect
human
middl
east
four
addit
human
cov
hcov
continu
circul
global
caus
respiratori
diseas
continu
circul
bat
popul
sarsand
merslik
cov
replic
effici
primari
human
airway
cell
demonstr
potenti
cov
emerg
caus
sever
diseas
futur
sarscov
merscov
outbreak
control
larg
public
health
measur
potenti
futur
outbreak
highlight
need
safe
effect
therapeut
combat
cov
infect
current
approv
therapeut
vaccin
human
cov
infect
previou
effort
treat
cov
infect
exist
antivir
conclus
benefit
clinic
outcom
thu
current
standard
care
remain
mostli
support
sever
target
directact
antivir
investig
treat
cov
infect
viral
replic
machineri
perform
essenti
role
genom
replic
therapeut
approv
treat
multipl
differ
viral
infect
aim
target
mani
approv
antivir
classifi
nucleosid
analogu
compound
mimic
natur
nucleosid
inhibit
viral
replic
inhibit
nucleosid
analogu
accomplish
varieti
mechan
common
mechan
action
includ
incorpor
analogu
viral
polymeras
induc
prematur
termin
strand
synthesi
loss
essenti
genet
inform
mutagenesi
previou
studi
report
nucleosid
analogu
ribavirin
rbv
potent
inhibit
cov
find
attribut
proofread
capabl
viral
exoribonucleas
exon
recent
report
demonstr
inhibit
wildtyp
wt
cov
nucleosid
analogu
galidesivir
remdesivir
compound
shown
efficaci
cov
administr
multipl
compound
simultan
may
requir
effect
treat
cov
infect
control
emerg
drug
resist
demonstr
viral
infect
hydroxycytidin
nhc
emori
institut
drug
develop
cytidin
analogu
recent
shown
inhibit
multipl
virus
includ
chikungunya
viru
venezuelan
equin
enceph
viru
veev
respiratori
syncyti
viru
rsv
hepat
c
viru
noroviru
influenza
iav
b
virus
ebola
viru
previou
report
demonstr
increas
introduct
transit
mutat
viral
genom
treatment
well
high
genet
barrier
resist
antivir
activ
nhc
also
report
human
well
sarscov
neither
nhc
mechan
action
nhc
resist
describ
cov
date
studi
investig
nhc
inhibit
resist
two
diverg
murin
hepat
viru
mhv
merscov
show
nhc
potent
inhibit
wt
mhv
merscov
minim
cytotox
also
demonstr
mhv
exon
proofread
activ
limit
measur
effect
sensit
nhc
observ
nhc
inhibit
profil
consist
mutagen
mechan
action
featur
accumul
transit
mutat
indic
high
genet
barrier
resist
experi
two
diverg
model
cov
mhv
epidem
circul
zoonot
cov
merscov
nhc
treatment
result
dosedepend
reduct
viral
titer
mhv
fig
merscov
fig
inhibit
result
effect
concentr
ec
mhv
fig
merscov
fig
detect
neglig
chang
cell
viabil
fig
cytotox
concentr
cc
valu
vero
cell
fig
antivir
activ
due
cytotox
select
index
mhv
merscov
togeth
result
confirm
potent
inhibit
nhc
nhc
inhibit
profil
cov
consist
mutagenesi
better
understand
mechan
nhc
inhibit
cov
replic
perform
time
drug
addit
assay
determin
point
viral
replic
cycl
nhc
act
ad
time
ec
nhc
indic
time
preor
postinfect
pi
cell
wt
mhv
multipl
infect
moi
pfucel
quantifi
viral
replic
singl
infecti
cycl
compar
vehicl
dimethyl
sulfoxid
dmso
control
nhc
significantli
inhibit
mhv
replic
ad
h
postinfect
fig
suggest
nhc
act
earli
stage
viral
replic
cycl
next
determin
effect
nhc
mhv
rna
level
compar
effect
infectiousviru
titer
rna
level
reduc
approxim
highest
test
concentr
nhc
mhvinfect
cell
monolay
fig
supernat
fig
contrast
viral
titer
reduc
concentr
therefor
calcul
ratio
infecti
viru
per
viral
rna
genom
copi
number
normal
untreat
control
specif
infect
nhc
treatment
found
specif
infect
wt
mhv
reduc
dosedepend
manner
treatment
increas
concentr
nhc
fig
togeth
data
consist
mutagen
mechan
nhc
anticov
activ
nhc
treatment
increas
transit
mutat
present
across
mhv
genom
directli
test
effect
nhc
treatment
mutat
burden
treat
wt
mhv
increas
concentr
nhc
perform
fullgenom
nextgener
sequenc
ng
viral
popul
releas
singl
round
infect
data
demonstr
dosedepend
increas
mutat
present
low
frequenc
viral
popul
across
genom
treatment
increas
concentr
nhc
fig
c
analysi
type
mutat
introduc
nhc
reveal
increas
total
number
transit
mutat
increas
nhc
concentr
fig
f
rel
proport
g
c
u
transit
among
observ
mutat
increas
presenc
nhc
presenc
nhc
compar
vehicl
control
fig
h
convers
rel
proport
g
u
c
transit
decreas
increas
nhc
concentr
compar
vehicl
control
fig
h
togeth
result
demonstr
nhc
treatment
singl
round
wt
mhv
infect
caus
predominantli
g
c
u
transit
mutat
detect
low
frequenc
across
genom
data
support
mutagen
mechan
action
nhc
inhibit
wt
mhv
nhc
inhibit
modestli
enhanc
absenc
exon
proofread
mutagen
nucleosid
analogu
rbv
ineffect
potent
inhibit
wt
cov
due
exon
proofread
activ
proofreadingdefici
exon
mhv
mutant
display
increas
sensit
previous
test
nucleosid
analogu
indic
proofread
dampen
inhibit
compound
therefor
test
sensit
exon
mhv
nhc
inhibit
result
indic
nhc
decreas
titer
wt
exon
mhv
dosedepend
manner
exon
mhv
demonstr
statist
passag
presenc
nhc
yield
lowlevel
resist
associ
multipl
transit
mutat
better
understand
develop
impact
nhc
resist
cov
passag
two
lineag
wt
mhv
time
presenc
increas
concentr
nhc
test
sensit
passag
mhv
popul
nhc
inhibit
found
lineag
mhv
viral
popul
show
chang
sensit
nhc
compar
wt
mhv
fig
howev
lineag
mhv
show
decreas
sensit
nhc
inhibit
titer
reduct
assay
especi
higher
concentr
compound
observ
modest
approxim
increas
ec
valu
mhv
nhc
passag
virus
wt
mhv
ec
mhv
ec
mhv
ec
fig
suggest
mhv
passag
result
minim
resist
nhc
next
sought
determin
passag
wt
mhv
presenc
nhc
alter
replic
capac
virus
found
lineag
show
delay
replic
ultim
reach
peak
titer
similar
wt
mhv
fig
delay
replic
suggest
mhv
less
fit
wt
mhv
identifi
mutat
associ
phenotyp
passag
sequenc
complet
genom
mhv
mhv
lineag
passag
presenc
nhc
accumul
consensu
mutat
distribut
across
genom
fig
e
see
tabl
supplement
materi
comparison
previou
studi
report
wt
mhv
accumul
total
mutat
passag
absenc
drug
analysi
mhv
mutat
profil
demonstr
slightli
total
mutat
lineag
synonym
chang
result
amino
acid
chang
oppos
nonsynonym
chang
alter
amino
acid
sequenc
fig
see
tabl
addit
vast
major
mutat
lineag
transit
mutat
result
purinetopurin
pyrimidinetopyrimidin
chang
fig
lineag
contain
two
transvers
mutat
result
purinetopyrimidin
pyrimidinetopurin
chang
though
possibl
transit
mutat
type
detect
virallineag
popul
major
passag
lineag
g
transit
fig
consist
mhv
ng
data
fig
determin
mutat
profil
consist
earlier
passag
analyz
whole
genom
lineag
lineag
demonstr
fewer
mutat
profil
synonym
versu
nonsynonym
chang
transit
mutat
similar
see
fig
tabl
supplement
materi
determin
whether
lack
robust
resist
nhc
broadli
applic
across
assess
capac
merscov
evolv
resist
nhc
fig
correspond
approxim
resist
similar
mhv
observ
substanti
shift
doserespons
curv
merscov
indic
minim
acquir
resist
nhc
virus
replic
similarli
wt
merscov
fig
sequenc
lineag
merscov
popul
detect
consensu
mutat
merscov
nhc
fig
see
tabl
supplement
materi
consensu
mutat
merscov
nhc
fig
see
tabl
randomli
distribut
across
genom
merscov
nhc
merscov
nhc
accumul
nonsynonym
synonym
mu
tation
roughli
equal
proport
fig
mhv
mutat
detect
merscov
lineag
predominantli
transit
mutat
fig
analysi
mutat
reveal
predomin
type
transit
lineag
depend
major
transit
mutat
merscov
nhc
g
transit
observ
mhv
lineag
wherea
merscov
nhc
contain
similar
number
type
fig
result
indic
merscov
achiev
lowlevel
resist
nhc
develop
resist
associ
accumul
multipl
transit
mutat
togeth
data
suggest
nhc
act
mutagen
pose
high
genet
barrier
resist
studi
demonstr
nhc
potent
inhibit
diverg
mhv
merscov
data
consist
virusmutagen
mechan
action
evidenc
decreas
specif
infect
increas
g
c
u
transit
mutat
present
low
frequenc
across
genom
treatment
nhc
also
demonstr
robust
resist
nhc
difficult
achiev
mhv
merscov
wt
mhv
exon
mhv
sensit
nhc
inhibit
suggest
nhc
abl
overcom
exonmedi
proofread
inhibit
wt
cov
interact
cov
differ
previous
test
nucleosid
analogu
util
broadspectrum
antivir
nhc
pancov
therapeut
earli
work
nhc
focus
mutagen
effect
compound
multipl
bacteri
system
recent
antivir
properti
compound
report
multipl
rna
virus
includ
chikungunya
viru
venezuelan
equin
enceph
viru
respiratori
syncyti
viru
hepat
c
viru
noroviru
influenza
b
virus
ebola
viru
nhc
also
shown
potent
inhibit
sarscov
suggest
potenti
util
treat
cov
infect
base
previou
studi
nhc
appear
primarili
inhibit
viral
replic
mutagenesi
serial
passag
presenc
nhc
led
lowlevel
resist
veev
detect
resist
rsv
iav
bovin
viral
diarrhea
viru
indic
high
barrier
resist
consist
previou
studi
demonstr
nhc
mutagen
cov
serial
passag
yield
lowlevel
approxim
resist
lowlevel
resist
also
observ
remdesivir
anoth
nucleosid
analogu
potent
inhibit
cov
approxim
resist
remdesivir
confer
two
mutat
cov
rnadepend
rna
polymeras
rdrp
studi
expand
known
antivir
spectrum
nhc
includ
mhv
merscov
two
genet
diverg
support
nhc
develop
broadspectrum
cov
antivir
nhc
inhibit
may
circumv
exonmedi
proofread
nhc
first
mutagen
nucleosid
analogu
demonstr
potent
inhibit
proofreadingintact
cov
previou
studi
demonstr
virus
lack
exon
proofread
activ
exon
virus
sensit
inhibit
nucleosid
analogu
especi
rbv
increas
sensit
attribut
inabl
exon
virus
effici
remov
incorrect
nucleosid
howev
observ
minim
chang
nhc
sensit
wt
mhv
exon
mhv
especi
ec
suggest
nhc
interact
cov
replicas
differ
previous
test
nucleosid
analogu
one
explan
nhc
may
evad
remov
proofread
exon
studi
investig
nucleosid
inhibit
dna
virus
suggest
inabl
viral
exonucleas
effici
excis
nucleosid
analogu
previou
studi
suggest
dna
exonucleas
activ
incap
remov
nhc
sarscov
exon
effici
remov
mismatch
regardless
type
effect
nhc
activ
investig
interestingli
mismatch
readili
observ
singlenucleotid
elong
sarscov
polymeras
absenc
drug
correspond
mismatch
would
lead
g
c
u
transit
observ
nhc
treatment
suggest
cov
polymeras
could
natur
prone
make
type
error
magnifi
nhc
could
lead
scenario
exon
prevent
dip
error
threshold
ultim
result
lethal
mutagenesi
similar
inhibit
wt
mhv
exon
mhv
sever
nucleosid
includ
mutagen
rbv
multipl
demonstr
mechan
direct
incorpor
genom
thu
anoth
explan
uniqu
potenc
nhc
presenc
activ
proofread
exon
may
inhibit
viral
replic
addit
mechan
beyond
mutagenesi
inde
previou
report
suggest
nhc
may
also
interfer
rna
secondari
structur
virion
releas
caus
inhibit
exogen
c
u
presenc
nhc
could
rescu
viral
replic
hcv
chikungunya
viru
rsv
influenza
viru
indic
nhc
compet
exogen
nucleosid
stage
prior
viral
inhibit
result
rais
possibl
nhc
could
inhibit
process
result
similar
inhibit
virus
mechan
unrel
exon
thu
futur
studi
import
investig
role
proofread
nhc
inhibit
cov
shed
light
intricaci
nhc
inhibit
cov
replic
complex
nhc
mutagenesi
may
hinder
emerg
robust
resist
nhc
decreas
specif
infect
along
accumul
transit
across
cov
genom
support
mutagen
mechan
action
nhc
cov
nhc
resist
cov
modest
difficult
achiev
obtain
approxim
resist
passag
resist
associ
multipl
mutat
interestingli
merscov
accumul
fewer
mutat
passag
mhv
differ
viral
mutat
rate
could
driver
differ
previou
studi
suggest
mhv
higher
mutat
rate
merscov
differ
mutat
accumul
mhv
merscov
may
product
differ
passag
condit
mhv
passag
consist
transfer
volum
merscov
passag
volum
adjust
time
sustain
viral
replic
escal
select
drug
resist
constantvolum
passag
condit
may
sever
bottleneck
mhv
popul
fix
mutat
genom
variablevolum
passag
condit
appli
merscov
altern
differ
could
also
reflect
differ
mutat
robust
mhv
merscov
genom
though
proposit
need
investig
portion
mutat
accumul
passag
like
contribut
nhc
resist
mutat
protein
dispens
viral
replic
cell
cultur
may
mere
toler
limit
effect
viral
fit
context
passag
condit
common
mutat
aros
mhv
merscov
passag
seri
see
tabl
suggest
multipl
pathway
lowlevel
nhc
resist
exist
cov
interestingli
mhv
merscov
lineag
demonstr
greater
chang
sensit
nhc
lineag
fewer
overal
mutat
fig
mhv
passag
lineag
replic
less
well
wt
mhv
suggest
accumul
mutat
passag
may
neg
impact
viral
fit
abil
mhv
evolv
robust
resist
nhc
mhv
lineag
result
chang
sensit
nhc
mhv
fewer
mutat
present
consensu
lineag
see
fig
thu
possibl
accumul
deleteri
mutat
counteract
potenti
benefit
resist
mutat
case
mutat
promot
nhc
resist
would
need
aris
earli
passag
help
mitig
accumul
excess
deleteri
mutat
altern
inabl
evad
inhibit
nhc
may
lead
accumul
greater
number
nhcassoci
transit
ultim
higher
mutat
burden
may
impact
viral
fit
togeth
result
support
hypothesi
establish
resist
nhc
cov
requir
delic
balanc
resistancepromot
mutat
viral
fit
accumul
deleteri
mutat
thu
defin
role
individu
nhc
resistanceassoci
mutat
import
goal
futur
studi
overal
result
support
develop
nhc
broadspectrum
antivir
treatment
cov
infect
contribut
new
insight
import
aspect
cov
replic
cell
cultur
murin
astrocytoma
delay
brain
tumor
dbt
vero
atcc
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
supplement
fetal
bovin
serum
fb
invitrogen
penicillin
streptomycin
gibco
amphotericin
b
corn
virus
work
mhv
perform
use
recombin
wt
strain
genbank
access
number
merscov
stock
gener
cdna
clone
genbank
access
number
compound
cell
viabil
studi
nhc
synthes
emori
institut
drug
develop
prepar
mm
stock
solut
dmso
cell
viabil
assess
use
celltiterglo
promega
plate
accord
manufactur
instruct
dbt
vero
cell
incub
indic
concentr
compound
h
dbt
h
vero
cell
viabil
determin
use
verita
micropl
luminomet
promega
glomax
promega
valu
normal
vehicletr
cell
nucleosid
analogu
sensit
studi
gener
ec
curv
subconflu
monolay
dbt
cell
infect
mhv
moi
pfu
per
cell
h
inoculum
remov
replac
medium
contain
indic
compound
concentr
cell
supernat
harvest
h
postinfect
titer
determin
plaqu
assay
describ
previous
subconflu
monolay
vero
cell
infect
moi
pfucel
merscov
viru
adsorpt
min
inoculum
remov
cell
wash
pb
incub
medium
contain
indic
concentr
nhc
dmso
vehicl
control
h
supernat
collect
titer
determin
plaqu
assay
describ
previous
ec
ec
valu
curv
gener
use
nonlinear
regress
curv
fit
graphpad
la
jolla
ca
prism
softwar
time
drug
addit
assay
subconflu
monolay
dbt
cell
treat
medium
contain
dmso
nhc
time
ec
indic
time
preor
postinfect
cell
infect
wt
mhv
moi
pfucel
h
viru
inoculum
remov
replac
fresh
medium
cultur
supernat
harvest
h
postinfect
viral
titer
determin
plaqu
assay
quantif
viral
genom
rna
subconflu
dbt
cell
infect
wt
mhv
moi
pfucel
inoculum
remov
h
incub
medium
contain
indic
concentr
nhc
ad
total
rna
cell
supernat
rna
harvest
use
trizol
reagent
invitrogen
h
total
rna
supernat
rna
extract
phase
separ
total
rna
purifi
ethanol
precipit
supernat
rna
purifi
use
purelink
rna
minikit
invitrogen
accord
manufactur
protocol
total
rna
revers
transcrib
use
superscript
iii
invitrogen
gener
cdna
quantifi
quantit
pcr
qpcr
previous
describ
data
present
denot
chang
threshold
cycl
viral
target
normal
control
dehydrogenas
gapdh
drug
treatment
supernat
rna
quantifi
use
onestep
quantit
revers
transcriptas
pcr
qrtpcr
previous
describ
data
present
fold
chang
genom
rna
copi
normal
vehicl
control
determin
specif
infect
subconflu
dbt
cell
infect
wt
mhv
moi
pfucel
inoculum
remov
h
incub
medium
contain
indic
concentr
nhc
ad
supernat
rna
harvest
use
trizol
reagent
invitrogen
h
follow
extract
quantif
describ
viral
titer
determin
plaqu
assay
specif
infect
calcul
number
pfu
divid
supernat
genom
rna
copi
number
ratio
normal
vehicl
control
ng
studi
subconflu
dbt
cell
infect
wt
mhv
moi
pfucel
treat
indic
concentr
nhc
supernat
collect
h
postinfect
purifi
viral
rna
submit
genewiz
south
plainfield
nj
librari
prepar
sequenc
briefli
qualiti
control
viral
rna
randomli
fragment
use
heat
librari
prepar
sequenc
illumina
hiseq
platform
genewiz
perform
base
call
read
demultiplex
trimmomat
use
trim
adapt
contamin
read
shorter
bp
filter
lowqual
base
q
score
pairedend
fastq
read
align
mhv
genom
use
gener
sam
file
samtool
use
process
result
align
file
calcul
coverag
depth
nucleotid
gener
sort
index
bam
file
lofreq
use
call
substitut
variant
includ
lowfrequ
variant
gener
variant
file
bash
shell
excel
use
process
analyz
result
vcf
file
frequenc
use
cutoff
variant
consist
previou
report
absolut
number
mutat
report
nhc
treatment
percentag
total
mutat
specif
mutat
type
calcul
use
number
differ
percentag
class
mutat
treatment
compar
vehicl
control
refer
rel
proport
mutat
mhv
popul
passag
presenc
nhc
wt
mhv
passag
triplic
increas
concentr
nhc
maximum
infect
initi
passag
moi
pfucel
viral
supernat
harvest
viral
lineag
frozen
cell
monolay
demonstr
cytopath
effect
cpe
h
constant
volum
l
use
initi
subsequ
passag
three
lineag
maintain
passag
lineag
demonstr
visibl
cpe
upon
multipl
attempt
vari
concentr
lineag
maintain
passag
passag
total
rna
harvest
infect
cell
monolay
use
trizol
reagent
viral
rna
extract
passag
passag
sampl
revers
transcrib
use
superscript
iii
follow
gener
pcr
amplicon
cover
whole
genom
dideoxi
amplicon
sequenc
perform
genewiz
analyz
identifi
mutat
present
greater
total
use
macvector
viral
mutat
map
depict
identifi
mutat
gener
use
macvector
merscov
popul
passag
presenc
nhc
three
parallel
independ
passag
seri
wt
merscov
perform
vero
cell
presenc
gradual
increas
concentr
nhc
maximum
concentr
select
drugresist
mutant
virus
viru
adapt
nhcsupplement
complet
cultur
medium
assess
monitor
progress
characterist
merscov
cpe
volum
transfer
cultur
supernat
adjust
empir
balanc
continu
select
pressur
cultur
extinct
triplic
lineag
merscov
passag
experi
sustain
passag
howev
third
lineag
sever
impair
replic
exclud
analysi
total
infectedcel
merscov
rna
purifi
monolay
infect
terminalpassag
cultur
supernat
use
gener
rtpcr
product
consensu
sanger
sequenc
complet
viral
genom
genewiz
chang
passag
viru
nucleotid
deduc
amino
acid
sequenc
identifi
via
align
wt
parent
viru
genom
sequenc
use
macvector
viru
replic
assay
subconflu
monolay
dbt
mhv
vero
merscov
cell
infect
wt
nhcpassag
viral
popul
moi
pfucel
h
mhv
min
merscov
inocula
remov
cell
wash
pb
addit
prewarm
medium
supernat
harvest
indic
time
postinfect
titer
determin
plaqu
assay
statist
statist
test
perform
use
graphpad
la
jolla
ca
prism
softwar
describ
respect
figur
legend
supplement
materi
articl
may
found
http
doi
